Cabo Developer Continues to Trim Pipeline
Exelixis, Sanofi Terminate Preclinical PI3K Programs
By Marie Powers
Tuesday, December 27, 2011
A day after inking a potential $251 million agreement with Merck & Co. Inc. to license out its phosphoinositide-3 kinase (PI3K)-delta research and development program, Exelixis Inc. trimmed its pipeline further, agreeing to terminate the preclinical programs that were part of a blockbuster 2009 PI3K collaboration with Sanofi-Aventis SA, of Paris.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.